Genmab upgrades financial guidance again
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13435562.ece/ALTERNATES/schema-16_9/doc7i9oi0cmd511140p9oja.jpg)
Sales of Darzalex, which is a bone marrow cancer drug, are significantly exceeding expectations, Genmab reports in a stock exchange notification.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Horizon's Genmab drug gets blockbuster status
For subscribers
Analysts say Darzalex sales prognosis could be too cautious
For subscribers